Guardant Health Highlights Shield Test Growth at Canaccord Conference
Guardant Health discussed the commercial progress and growth trajectory of its Shield product at the Canaccord Growth Conference.
Guardant Health executives highlighted the performance and commercial expansion of its Shield colorectal cancer screening test during a presentation at the Canaccord Growth Conference.
Management discussed how adoption of the Shield test is driving core business growth, detailing strategic initiatives and operational milestones for the diagnostic product. The company provided updates on market penetration and future growth prospects within the diagnostics sector.
Helena covers corporate news for listed and private companies across Europe, from strategy shifts to leadership changes, with an eye for what a story signals about the broader market.
More from Helena Vásquez →
